Sotonye Esedu Imadojemu, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoidosis | 8 | 2024 | 521 | 3.780 |
Why?
|
Skin Diseases | 10 | 2024 | 1094 | 3.180 |
Why?
|
Dermatology | 6 | 2022 | 918 | 1.060 |
Why?
|
Granuloma | 4 | 2023 | 328 | 0.910 |
Why?
|
Cosmetic Techniques | 3 | 2013 | 149 | 0.830 |
Why?
|
Moral Obligations | 2 | 2013 | 93 | 0.810 |
Why?
|
Informed Consent | 2 | 2013 | 1008 | 0.530 |
Why?
|
Patients | 2 | 2013 | 907 | 0.530 |
Why?
|
Yellow Nail Syndrome | 1 | 2015 | 2 | 0.520 |
Why?
|
Triamcinolone Acetonide | 1 | 2015 | 100 | 0.480 |
Why?
|
Fluconazole | 1 | 2015 | 157 | 0.480 |
Why?
|
Pilomatrixoma | 1 | 2014 | 24 | 0.460 |
Why?
|
Hair Diseases | 1 | 2014 | 72 | 0.440 |
Why?
|
Skin Pigmentation | 1 | 2013 | 277 | 0.370 |
Why?
|
Scalp | 1 | 2014 | 389 | 0.370 |
Why?
|
Antifungal Agents | 1 | 2015 | 752 | 0.350 |
Why?
|
Necrobiosis Lipoidica | 2 | 2019 | 14 | 0.330 |
Why?
|
Ethics, Medical | 1 | 2013 | 783 | 0.300 |
Why?
|
Face | 1 | 2013 | 1026 | 0.290 |
Why?
|
Cyclosporine | 2 | 2020 | 778 | 0.290 |
Why?
|
Anti-Inflammatory Agents | 1 | 2015 | 1809 | 0.250 |
Why?
|
Skin | 4 | 2023 | 4484 | 0.230 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3461 | 0.180 |
Why?
|
Chronic Disease | 3 | 2023 | 9318 | 0.180 |
Why?
|
Erythema Nodosum | 1 | 2020 | 31 | 0.180 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2020 | 10 | 0.180 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2020 | 14 | 0.180 |
Why?
|
Granuloma Annulare | 1 | 2019 | 29 | 0.160 |
Why?
|
Lymphatic Diseases | 1 | 2020 | 320 | 0.160 |
Why?
|
Physicians | 1 | 2016 | 4591 | 0.150 |
Why?
|
Diagnosis, Differential | 2 | 2023 | 12974 | 0.140 |
Why?
|
Dermatomyositis | 2 | 2017 | 258 | 0.140 |
Why?
|
Paraproteinemias | 1 | 2020 | 248 | 0.140 |
Why?
|
Education, Distance | 1 | 2020 | 261 | 0.140 |
Why?
|
Dermatitis Herpetiformis | 1 | 2016 | 23 | 0.140 |
Why?
|
Skin Neoplasms | 2 | 2016 | 5821 | 0.120 |
Why?
|
Hair Follicle | 1 | 2017 | 211 | 0.120 |
Why?
|
Humans | 27 | 2024 | 761504 | 0.120 |
Why?
|
Injections, Intralesional | 1 | 2015 | 280 | 0.120 |
Why?
|
Pemphigoid, Bullous | 1 | 2016 | 112 | 0.120 |
Why?
|
Lactation | 1 | 2016 | 397 | 0.110 |
Why?
|
Skin Care | 1 | 2013 | 57 | 0.110 |
Why?
|
Drug Eruptions | 1 | 2016 | 335 | 0.110 |
Why?
|
Alopecia | 1 | 2017 | 412 | 0.100 |
Why?
|
Rejuvenation | 1 | 2013 | 107 | 0.100 |
Why?
|
Dermatologic Agents | 1 | 2016 | 313 | 0.100 |
Why?
|
Career Choice | 1 | 2016 | 756 | 0.080 |
Why?
|
Education, Medical | 1 | 2020 | 1725 | 0.080 |
Why?
|
Databases, Factual | 1 | 2024 | 7967 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26125 | 0.070 |
Why?
|
Autoimmune Diseases | 2 | 2016 | 2244 | 0.070 |
Why?
|
Goals | 1 | 2012 | 711 | 0.070 |
Why?
|
Antigens, CD | 1 | 2017 | 4003 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2024 | 4811 | 0.070 |
Why?
|
Sinusitis | 1 | 2015 | 991 | 0.070 |
Why?
|
Middle Aged | 10 | 2024 | 220895 | 0.070 |
Why?
|
Immunotherapy | 1 | 2021 | 4652 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6310 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4369 | 0.060 |
Why?
|
Counseling | 1 | 2012 | 1547 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4544 | 0.060 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2013 | 1188 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4580 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3051 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 2016 | 2155 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2016 | 2947 | 0.050 |
Why?
|
Male | 9 | 2024 | 360804 | 0.050 |
Why?
|
Female | 11 | 2024 | 392644 | 0.050 |
Why?
|
Adult | 7 | 2024 | 221177 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2020 | 80636 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5840 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2022 | 713 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29625 | 0.040 |
Why?
|
Coronary Vessels | 1 | 2011 | 3096 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9177 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2020 | 385 | 0.040 |
Why?
|
Endothelial Cells | 1 | 2011 | 3548 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3522 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2017 | 114 | 0.040 |
Why?
|
Faculty | 1 | 2020 | 384 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 12947 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10209 | 0.030 |
Why?
|
Ultraviolet Therapy | 1 | 2016 | 84 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.030 |
Why?
|
Scleroderma, Localized | 1 | 2016 | 87 | 0.030 |
Why?
|
Pemphigus | 1 | 2016 | 107 | 0.030 |
Why?
|
Antiphospholipid Syndrome | 1 | 2016 | 165 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2281 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13639 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2880 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2020 | 22176 | 0.020 |
Why?
|
Administration, Oral | 1 | 2020 | 4021 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
Scleroderma, Systemic | 1 | 2016 | 344 | 0.020 |
Why?
|
Quality of Life | 1 | 2013 | 13367 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2019 | 868 | 0.020 |
Why?
|
Neck | 1 | 2016 | 734 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2020 | 2161 | 0.020 |
Why?
|
Head | 1 | 2016 | 924 | 0.020 |
Why?
|
Lung Diseases, Interstitial | 1 | 2017 | 918 | 0.020 |
Why?
|
Fibrosis | 1 | 2016 | 2049 | 0.020 |
Why?
|
Aged | 5 | 2020 | 169289 | 0.020 |
Why?
|
Students, Medical | 1 | 2020 | 1936 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8631 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8830 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3743 | 0.020 |
Why?
|
Inflammation | 2 | 2017 | 10773 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8002 | 0.020 |
Why?
|
United States | 1 | 2013 | 72334 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10508 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2020 | 64680 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15842 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5146 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 3763 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8654 | 0.010 |
Why?
|
Hypertension | 1 | 2019 | 8540 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4431 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 39967 | 0.010 |
Why?
|
Melanoma | 1 | 2016 | 5709 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 41487 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29874 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2019 | 58976 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 59243 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74206 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 88319 | 0.010 |
Why?
|
Animals | 1 | 2016 | 168459 | 0.000 |
Why?
|